依那西普联合沙利度胺治疗强直性脊柱炎的临床研究

目的评价肿瘤坏死因子抑制剂依那西普联合沙利度胺治疗强直性脊柱炎（AS）的临床疗效和安全性。方法应用依那西普治疗52例AS患者，25mg／次，每周1次，疗程12周，同时加用沙利度胺50—100mg每晚一次，记录治疗前后患者的症状、体征、AS疾病活动指数（BASDAI）、AS的功能指数（BASFI）、红细胞沉降率（ESR）及C-反应蛋白（CRP）等实验室指标及不良反应。结果依那西普治疗后患者的脊柱痛与夜间痛程度、晨僵时间均改善，指地距、BASDAI、BASFI均下降，与治疗前比较均有统计学差异（P〈0．05）。最常见的不良反应主要是注射部位反应和上呼吸道感染。结论依那西普联合沙利度胺对AS有显著的临床疗效，无严重不良反应。

Clinical study of low-dosage etanercept combined with thalidomide for treatment of ankylosing spondylitis

Objective To evaluate the efficacy and safety of etanercept a tumor necrosis factor（TNF）- α inhibitor] and thalidomide in treatment of patients with ankylosing spondylitis （ AS ）. Methods Fifty - two patients with AS received etanercept 25 mg once a week for a therapeutic course of 12 weeks in addition with thalidomide 50 - 100mg once a day. Symptoms, signs, Bath Ankylosing Spondylitis Disease Activity Index（BASDAI） , Bath Ankylosing Spondylitis Functional Index（BASFI） , erythrocyte sedimentation rate（ESR） , C -reactive protein（CRP） levels and side effects were observed before and ＇after treatment. Results All patients completed treatment course. The degree of spinal pain and nocturnal pain, duration of morning stiffness, finger - to - floor distance, BASDAI and BASFI were significantly improved after treatment （ P 〈 0.05 ）. The most common adverse reactions of etanercept included injection site reaction and upper respiratory infection. Conclusion The treatment with low - dosage etanercept combined with thalidomide has obvious therapeutic effect on AS without serious adverse reactions.